Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 5

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 5
---
 pre-clinical studies and clinical trials, and the general condition of the securities markets at the time of this offering.

This offering will terminate on October 2, 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per share (or pre-funded warrant) and accompanying common warrants will be fixed for the duration of this offering.

We have engaged H.C. Wainwright
& Co., LLC (the “Placement Agent”) to act as our exclusive placement agent in connection with this offering. The
Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The
Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required to arrange
the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the Placement Agent the placement
agent fees set forth in the table, which assumes that we sell all of the securities offered by this prospectus. There is no minimum offering
requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing
this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received
by us. We will bear all costs associated with the offering and investors in this offering will not receive a refund in the event that
we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. There is no arrangement
for funds to be received in escrow, trust or similar arrangement. Because there is no escrow account and no minimum offering amount,
investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives
due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our
immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. See “Plan of Distribution” on page 16 of this prospectus for more information regarding these arrangements

|                                         |     | Per Share and       
 Accompanying Common 
 Warrants            |     | Per Pre-Funded           
 Warrant and Accompanying 
 Common Warrants          |     | Total |
|